Seminars in Oncology
Volume 33 , Pages 15-18 , June 2006

Protein Kinase C-β as a Therapeutic Target in Breast Cancer

  • George W. Sledge Jr

      Affiliations

    • Corresponding Author InformationAddress reprint requests to George W. Sledge, Jr, MD, Departments of Medicine and Pathology, Indiana University Cancer Center, RT-473, Indianapolis, IN 46220, USA.
    • ,
  • Yesim Gökmen-Polar

References 

  1. Fields AP , Gustafson WC . Protein kinase C in disease . In:  Newton AC editors. Methods in Molecular Biology, vol 233 (Protein kinase C protocols) . Totowa, NJ: Humana Press Inc; 2003;p. 519–537
  2. Goekjian PG , Jirousek MR . Protein kinase C inhibitors as novel anticancer drugs . Expert Opin Invest Drugs . 2001;10:2117–2140
  3. Hofmann J . Protein kinase C isozymes as potential targets for anticancer therapy . Curr Cancer Drug Targets . 2004;4:125–146
  4. Nishizuka Y . The molecular heterogeneity of protein kinase C and its implications for cellular regulation . Nature . 1988;334:661–665
  5. Hug H , Sarre TF . Protein kinase C isoenzymes (Divergence in signal transduction?) . Biochem J . 1993;291:329–343
  6. Hocevar BA , Morrow DM , Tykocinski ML , et al.   Protein kinase C isotypes in human erythroleukemia cell proliferation and differentiation . J Cell Sci . 1992;101:671–679
  7. Murray NR , Baumgardner GP , Burns DJ , et al.   Protein kinase C isotypes in human erythroleukemia (K562) cell proliferation and differentiation (Evidence that βII protein kinase C is required for proliferation) . J Biol Chem . 1993;268:15847–15853
  8. Ono Y , Kikkawa U , Ogita K , et al.   Expression and properties of two types of protein kinase C (Alternative splicing from a single gene) . Science . 1987;236:1116–1120
  9. Murray NR , Davidson LA , Chapkin RS , et al.   Overexpression of protein kinase C βII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis . J Cell Biol . 1999;145:699–711
  10. Black JD . Protein kinase C isozymes in colon carcinogenesis (Guilt by omission) . Gastroenterology . 2001;120:1868–1872
  11. Gökmen-Polar Y , Murray NR , Velasco MA , et al.   Elevated protein kinase C beta II is an early promotive event in colon carcinogenesis . Cancer Res . 2001;61:1375–1381
  12. Zhang J , Anastasiadis PZ , Liu Y , et al.   Protein kinase C (PKC) βII induces cell invasion through a Ras/Mek-, PKCiota/Rac 1-dependent signaling pathway . J Biol Chem . 2004;279:22118–22123
  13. Suga K , Sugimoto I , Ito H , et al.   Down-regulation of protein kinase C alpha detected in human colorectal cancer . Biochem Mol Biol Int . 1998;44:523–528
  14. Davidson LA , Brown RE , Chang WC , et al.   Morphodensitometric analysis of protein kinase C beta (II) expression in rat colon (Modulation by diet and relation to in situ cell proliferation and apoptosis) . Carcinogenesis . 2000;21:1513–1519
  15. Klein IK , Ritland SR , Burgart LJ , et al.   Adenoma-specific alterations of protein kinase C expression in Apc(MIN) mice . Cancer Res . 2000;60:2077–2080
  16. Shipp MA , Ross KN , Tamayo P , et al.   Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning . Nat Med . 2002;8:68–74
  17. da Rocha AB , Mans DR , Regner A , et al.   Targeting protein kinase C (New therapeutic opportunities against high-grade malignant gliomas?) . Oncologist . 2002;7:17–33
  18. Su TT , Guo B , Kawakami Y , et al.   PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling . Nat Immunol . 2002;3:780–786
  19. O’Brian CA , Vogel VG , Singletary SE , et al.   Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue . Cancer Res . 1989;49:3215–3217
  20. Gordge PC , Hulme MJ , Clegg RA , et al.   Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue . Eur J Cancer . 1996;32A:2120–2126
  21. Borner C , Wyss R , Regazzi R , et al.   Immunological quantitation of phospholipid/Ca2+-dependent protein kinase of human mammary carcinoma cells (Inverse relationship to estrogen receptors) . Int J Cancer . 1987;40:344–348
  22. Lee SA , Karaszkiewicz JW , Anderson WB . Elevated level of nuclear protein kinase C in multidrug-resistant MCF-7 human breast carcinoma cells . Cancer Res . 1992;52:3750–3759
  23. Kiley SC , Clark KJ , Duddy SK , et al.   Increased protein kinase Cδ in mammary tumor cells (relationship to transformation and metastasic progression) . Oncogene . 1999;18:6748–6757
  24. Kiley SC , Clark KJ , Goodnough M , et al.   Protein Kinase Cδ involvement in mammary tumor cell metastasis . Cancer Res . 1999;59:3230–3238
  25. Lahn M , Köhler G , Sundell K , et al.   Protein kinase C alpha expression in breast and ovarian cancer . Oncology . 2004;67:1–10
  26. Ways DK , Kukoly CA , deVente J , et al.   MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype . J Clin Invest . 1995;95:1906–1915
  27. Morse-Gaudio M , Connolly JM , Rose DP . Protein kinase C and its isoforms in human breast cancer cells (Relationship to the invasive phenotype) . Int J Oncol . 1998;12:1349–1354
  28. Manni A , Buckwalter E , Etindi R , et al.   Induction of a less aggressive breast cancer phenotype by protein kinase C-α and β-overexpression . Cell Growth Differ . 1996;7:1187–1198
  29. Nabha SM , Glaros S , Hong M , et al.   Upregulation of PKCδ contributes to antiestrogen resistance in mammary tumor cells . Oncogene . 2005;24:3166–3176
  30. Chalfant CE , Mishak H , Watson JE , et al.   Regulation of alternative splicing of protein kinase C beta by insulin . J Biol Chem . 1995;270:13326–13332
  31. Xia P , Aiello LP , Ishii H , et al.   Characterization of vascular endothelial growth factor’s effect on the activation of protein kinase C, its isoforms, and endothelial cell growth . J Clin Invest . 1996;98:2018–2026
  32. Takahashi T , Ueno H , Shibuya M . VEGF activates protein kinase C-dependent, but Ras independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells . Oncogene . 1999;18:2221–2230
  33. Zachary I . VEGF signaling (integration and multi-tasking in endothelial cell biology) . Biochem Soc Trans . 2003;6:1171–1177
  34. Yoshiji H , Kuriyama S , Ways DK , et al.   Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis . Cancer Res . 1999;59:4413–4418
  35. Miller KD , Wang M , Gralow JD , et al.   E2100 (A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer) . Orlando, FL: Presented at the 41st Annual Meeting of the American Society of Clinical Oncology; 2004; May 13-17
  36. Graff JR , McNulty AM , Hanna KR , et al.   The protein kinase cb-selective inhibitor, enzastaurin (LY317615.HCL), supressess signaling through the Akt pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts . Cancer Res . 2005;65:7462–7469
  37. Teicher BA , Alvarez E , Menon K , et al.   Antiangiogenic effects of a protein kinase Cβ-selective small molecule . Cancer Chemother Pharmacol . 2002;49:69–77
  38. Keyes KA , Mann L , Sherman M , et al.   LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice . Cancer Chemother Pharmacol . 2004;53:133–140
  39. Teicher BA , Menon K , Alvarez E , et al.   Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human breast cancer and ovarian cancer xenografts . Invest New Drugs . 2002;20:241–251
  40. Herbst RS , Thornton DE , Kies MS , et al.   Phase 1 study of LY317615, a protein kinase Cb inhibitor . Proc Am Soc Clin Oncol . 2002;21:326; abstr
  41. Rademaker-Lakhai JM . Phase I and pharmacologic study of enzastaurin HCl, gemcitabine and cisplatin . Proc Am Soc Clin Oncol . 2004;24:3129; abstr
  42. Fine HA , Royce KM , Draper D , et al.   Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas . Proc Am Soc Clin Oncol . 2005;23:1504; abstr
  43. Robertson M , Kahl B , Vose J , et al.   A phase II study of enzastaurin, a protein kinase C-β (PKCβ) inhibitor, in the treatment of relapsed diffuse large B-cell lymphoma (DLBCL) . Blood . 2005;106:934; abstr

 Dr Sledge’s work is supported in part by a grant from the Breast Cancer Research Foundation and the Walther Medical Foundation.

PII: S0093-7754(06)00139-4

doi: 10.1053/j.seminoncol.2006.03.019

Seminars in Oncology
Volume 33 , Pages 15-18 , June 2006

Article Tools

* Image Usage & Resolution